The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access.

BACKGROUND We recently have shown a high incidence of unexplained pulmonary hypertension (PHT) in end-stage renal disease (ESRD) patients on chronic haemodialysis (HD) therapy via arterio-venous (A-V) access. This study evaluated the possibility that PHT in these patients is triggered or aggravated by chronic HD via surgical A-V access, and the role of endothelin-1 (ET-1) and nitric oxide (NO) in this syndrome. METHODS Forty-two HD patients underwent clinical evaluation. Pulmonary artery pressure (PAP) was evaluated using Doppler echocardiography. Levels of ET-1 and NO metabolites in plasma were determined before and after the HD procedure and were compared between subgroups of patients with and without PHT. RESULTS Out of 42 HD patients studied, 20 patients (48%) had PHT (PAP = 46+/-2; range 36-82 mmHg) while the rest had a normal PAP (29+/-1 mmHg) (P<0.0001). HD patients with PHT had higher cardiac output compared with those with normal PAP (6.0+/-1.2 vs 5.2+/-0.9 l/min, P<0.034). HD patients, with or without PHT, had elevated plasma ET-1 levels compared with controls (1.6+/-0.7 and 2.4+/-0.8 fmol/ml vs 1.0+/-0.2, P<0.05) that remained unchanged after the HD procedure. HD patients without PHT and control subjects showed similar basal plasma levels of NO2 + NO3 (24.2+/-5.2 vs 19.7+/-3.1 microM, P>0.05) that was significantly higher compared with HD patients with PHT (14.3+/-2.3 microM, P<0.05). HD therapy caused a significant increase in plasma NO metabolites that was greater in patients without PHT (from 24.2+/-5.2 to 77.1+/-9.6 microM, P<0.0001, and from 14.3+/-2.3 to 39.9+/-11.4 microM, P<0.0074, respectively). Significant declines in PAP (from 49.8+/-2.8 to 38.6+/-2.2 mmHg, P<0.004) and cardiac output (CO) (from 7.6+/-0.6 to 6.1+/-0.3 l/min, P<0.03) were found in 11 HD patients with PHT that underwent successful transplantation. Similarly, temporary closure of the A-V access by a sphygmomanometer in eight patients with PHT resulted in a transient decrease in CO (from 6.4+/-0.6 to 5.3+/- 0.5 l/min, P = 0.18) and systolic PAP (from 47.2+/-3.8 to 34.6+/-2.8 mmHg, P<0.028). CONCLUSIONS This study demonstrates a high prevalence of PHT among patients with ESRD on chronic HD via a surgical A-V fistula. In view of the vasodilatory and antimitogenic properties of NO, it is possible that the attenuated basal and HD-induced NO production in patients with PHT contributes to the increased pulmonary vascular tone. Furthermore, the partial restoration of normal PAP and CO in HD patients that underwent either temporal A-V shunt closure or successful transplantation indicates that excessive pulmonary blood flow is involved in the pathogenesis of the disease.

[1]  J. Krishnan,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[2]  M. Yigla,et al.  Pulmonary hypertension in patients with end-stage renal disease. , 2003, Chest.

[3]  R. Naeije Pulmonary vascular resistance. A meaningless variable? , 2003, Intensive care medicine.

[4]  R. Naeije Pulmonary vascular resistance , 2003 .

[5]  N. Morrell,et al.  Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. , 2002, Progress in cardiovascular diseases.

[6]  J. Donohoe,et al.  Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  T. Dschietzig,et al.  Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. , 2001, Biochemical and biophysical research communications.

[8]  N. Vaziri Effect of chronic renal failure on nitric oxide metabolism. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  E. Mervaala,et al.  Clinically important factors influencing endothelial function. , 2001, Medical science monitor : international medical journal of experimental and clinical research.

[10]  S. Rich,et al.  Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". , 2000, Circulation.

[11]  S. Oparil,et al.  Endothelial dysfunction in the pulmonary vascular bed. , 2000, The American journal of the medical sciences.

[12]  M. Yigla,et al.  Background diseases in 671 patients with moderate to severe pulmonary hypertension. , 2000, The Israel Medical Association journal : IMAJ.

[13]  A. Jardine,et al.  The vascular endothelium in chronic renal failure. , 2000, Journal of nephrology.

[14]  M. Hijmering,et al.  Nitric oxide production is reduced in patients with chronic renal failure. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Giaid Nitric oxide and endothelin-1 in pulmonary hypertension. , 1998, Chest.

[16]  L. Rubin,et al.  Pathology and pathophysiology of primary pulmonary hypertension. , 1995, The American journal of cardiology.

[17]  J. Stamler,et al.  Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. , 1994, Circulation.

[18]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[19]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[20]  S. Oparil,et al.  Endothelin and pulmonary hypertension. , 2000, Journal of cardiovascular pharmacology.

[21]  W. Markiewicz,et al.  Septal/free wall curvature ratio: a noninvasive index of pulmonary arterial pressure. , 1994, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.